2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. SGLT

SGLT

Sodium-dependent glucose cotransporters

SGLT

Related Products

PDF 0.51 MB

SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption. The two most well-known members of SGLT family are SGLT1 and SGLT2, which are members of the SLC5A gene family. The two transporters are of primary importance for glucose homeostasis by absorbing glucose from the diet in the small intestine (via SGLT1) and by reabsorbing the filtered glucose in the tubular system of the kidney (primarily SGLT2; to smaller extent via SGLT1); the latter process returns glucose into the blood stream and prevents urinary glucose loss. SGLT1 and SGLT2 have been proposed as a novel therapeutic strategy for diabetes and cardiomyopathy.

SGLT Isoform Specific Products:

SGLT Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-15409
    Empagliflozin
    		Inhibitor 99.90%
    Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
    Empagliflozin
  • HY-10450
    Dapagliflozin
    		Inhibitor 99.97%
    Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin
  • HY-10451
    Canagliflozin
    		Inhibitor 99.80%
    Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
    Canagliflozin
  • HY-N0142
    Phloretin
    		Inhibitor 99.67%
    Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.
    Phloretin
  • HY-15516
    Sotagliflozin
    		Inhibitor 99.89%
    Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
    Sotagliflozin
  • HY-I1120
    SGLT2-IN-1
    		Inhibitor ≥98.0%
    SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC50 of 33 nM.
    SGLT2-IN-1
  • HY-15461S1
    Ertugliflozin-d9
    		Inhibitor
    Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin-d<sub>9</sub>
  • HY-N4100R
    Trilobatin (Standard)
    		Inhibitor
    Trilobatin (Standard) is the analytical standard of Trilobatin. This product is intended for research and analytical applications. Trilobatin, a natural sweetener derived from?Lithocarpus polystachyus?Rehd, Trilobatin?is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells.
    Trilobatin (Standard)
  • HY-15461
    Ertugliflozin
    		Inhibitor 99.92%
    Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin
  • HY-N0143
    Phlorizin
    		Inhibitor 99.93%
    Phlorizin (Floridzin) is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor.
    Phlorizin
  • HY-17638
    Mizagliflozin
    		Inhibitor 98.87%
    Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.
    Mizagliflozin
  • HY-14894
    Ipragliflozin
    		Inhibitor 99.78%
    Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.
    Ipragliflozin
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
    		Inhibitor 99.99%
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)
  • HY-I0383
    Canagliflozin hemihydrate
    		Inhibitor 99.95%
    Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
    Canagliflozin hemihydrate
  • HY-N4100
    Trilobatin
    		Inhibitor 99.00%
    Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd, Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells.
    Trilobatin
  • HY-13413
    Tofogliflozin (hydrate)
    		Inhibitor 98.48%
    Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2. Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells.
    Tofogliflozin (hydrate)
  • HY-123797
    KGA-2727
    		Inhibitor 98.84%
    KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy.
    KGA-2727
  • HY-109092
    Licogliflozin
    		Inhibitor ≥98.0%
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
    Licogliflozin
  • HY-14945
    Remogliflozin etabonate
    		Inhibitor 99.81%
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.
    Remogliflozin etabonate
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid
    		Inhibitor 99.84%
    Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin L-pyroglutamic acid
SGLT Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.